A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
NCT06188325
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Gaucher's Disease
Interventions
DRUG:
Eliglustat
Sponsor
Sanofi